Cannabinor

Thuốc Gốc

Small Molecule

Cannabinor a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

Cơ Chế Tác Dụng : Cannabinor a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic. CB2 agonists bind to CB2 receptors, which are located on immune and inflammatory cells. By activating CB2 receptors, CB2 agonists inhibit autoimmune and inflammatory processes and are likely to be useful for treating pain, autoimmune and inflammatory disorders. Pharmos is developing its CB2 agonists as treatments for chronic pain and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Chỉ Định : Investigated for use/treatment in pain (acute or chronic).

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB05048

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading